RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

RenovoRx, Inc. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.
  • RenovoRx, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -9.69 M, a -123.84% change year over year.
  • RenovoRx, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -4.33 M.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
NasdaqCM: RNXT

RenovoRx, Inc.

CEO Mr. Shaun R. Bagai
IPO Date Aug. 26, 2021
Location United States
Headquarters 4546 El Camino Real
Employees 8
Sector Health Care
Industries
Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Similar companies

SABS

SAB Biotherapeutics, Inc.

USD 3.55

-3.00%

VRAX

Virax Biolabs Group Limited

USD 2.29

-3.78%

NTRB

Nutriband Inc.

USD 4.16

-1.65%

MNPR

Monopar Therapeutics Inc.

USD 24.98

-2.76%

ELDN

Eledon Pharmaceuticals, Inc.

USD 3.71

-4.63%

ADIL

Adial Pharmaceuticals, Inc.

USD 1.02

0.99%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

LGVN

Longeveron Inc.

USD 1.81

2.26%

KTTA

Pasithea Therapeutics Corp.

USD 2.53

-3.44%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email